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The /?-adrenergic antagonist propranolol was activated through its side chain, coupled to bovine serum al- 
bumin, and injected into BALB/c mice. After fusion of the splenocytes from these immunized mice with 
the NS-1 myeloma cell line, two hybridomas, producing monoclonal anti-propranolol antibodies, were 
isolated. Clone P-49 was monospecific for propranolol, with a significant preference for the 1-stereoisomer, 
as compared to the d form. On the other hand, clone P-28 cross-reacted with alprenolol as well as some 
other p-antagonists. Both classes of antibodies competed with A431 epidermoid carcinoma fi,-adrenocep- 
tors for the binding of [3H]propranolol. When ascites cells from clone P-28 were fixed with glutaraldehyde, 
the anti-propranolol monoclonal antibody became cell bound. These cell-bound P-28 antibodies bind pro- 
pranolol and other /?-adrenergic ligands with a similar ranking order to the soluble monoclonal antibody. 
The cell-bound antibody displayed a 5-fold higher affinity towards I-propranolol than the soluble mono- 
clonal antibody. The practical implications of these findings are discussed. 
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1. INTRODUCTION 
Catecholamines ynthesized in nerve terminals 
or in the chromaphine granules specifically interact 
with membrane-bound ,& as well as ai- and 
cl*-adrenergic receptors. The interaction of & 
adrenergic agonists with &adrenergic receptors 
triggers the activation of adenylate cyclase, which 
induces a cascade of biochemical events leading to 
the final physiological response [1,2]. In contrast, 
binding of the fl-adrenergic antagonists to these 
receptors mediates a reverse effect by competing 
with the &adrenergic agonists. 
Elucidation of the interaction properties be- 
tween P-agonists and/or &antagonists with ,& 
receptors is an important goal in understanding the 
mechanism of catecholamines and P-antagonist 
drugs at a molecular level. The widespread use of 
&blockers in the control of blood hypertension 
[3] led to an increased medical interest in 
adrenergic receptors. However, one of the major 
/3-Adrenergic receptor fl-Adrenergic antagonist 
obstacles in studying this interaction is associated 
with the necessity to purify large quantities of 
functionally active P-receptors. Hence, it is not 
surprising that a new line of investigation, based 
on immunological methods, has been initiated in 
recent years [4-61. Development of specific an- 
tibodies to p-agonists, &antagonists and fl- 
receptors should provide new tools to study this 
important biological system [7-91. 
Special attention should be paid to the 
stereospecificity of the ,f3-adrenergic receptors 
towards both agonists and antagonists [ 10-131. 
The present study was undertaken to (i) develop a 
chemically active propranolol molecule, (ii) use it 
for the development of an appropriate im- 
munogen, (iii) develop monoclonal antibodies 
(McAb) with stereospecificity for the biologically 
active isomer 1-propranolol and (iv) use these 
McAbs for the production of an artificial cell- 
bound receptor. 
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2. MATERIALS AND METHODS 
Propranolof, alprenolof, pindolol and cateehol- 
amines were from Sigma, The I- and d-stereoiso- 
mers of propranolol were obtained from ICI, 
England. All other chemicais were of analytical 
grade, 
2.2. Synthesis of ‘propranolol-amine’ 
The propranolol-amine, i.e. 2-[2-hydroxy-3-(i- 
naphthoxy)propylamino]-l-tert-butyloxycarbonyl- 
amino-2-methylpropane (compound III) was syn- 
thesized according to the scheme shown in fig-l. 
Compound I (l-naphthoxy-2,3~poxypropane~ 
$141 was prepared by mixing cr-naphthol (14.4 g, 
0.1 mol) and NaOH (4 g, 0.1 mol) in Hz0 (4 ml), 
heating for l-2 min, cooling and adding epichlo- 
rohydrin (10.1 g, 0.11 mo1). After stirring over- 
night at room temperature ether (100 ml) was 
added, after which the mixture was filtered. The 
filtrate was dried and solvent removed under 
reduced pressure. Part of the crude product (1.6 g) 
was dissolved in dichloromethane (2 ml) and 
loaded onto a silica gel column equilibrated with 
petroleum ether (40~WC b-p.). The same solvent 
was used to elute the product which appeared as 
the first peak, as monitored at 254 nm. Removal 
of the solvent from the pooled fractions containing 
the relevant peak yielded 0.78 g (40%) clear oily 
epoxide, which was identified by TLC (silica) with 
an Rf 0.74, using dichloromethane as solvent. 
O-No 0 
tCICH*C*%$ - 
PH FH3 
O-CH$U C!+$JH 5 CH$#f8oc 
‘“3 
For the synthesis of compound II (1-N-t-bu- 
tyloxycarboxylamino-2-Gino-2-m~thylpropane) a 
solution of ~-~-butyldi~bonat~ (3.65 g, 
0.0165 mol) in ~chloromethan~ (fOO ml) was 
slowly added (20 h) to a stirring solution of 
1.2-diamino~2”methylpropane (5 ml, 0.05 mol) in 
dichloromethane (100 ml). Addition of 1 N NaOH 
(60 ml, saturated with NaCl) was followed by 
phase separation. The aqueous phase was washed 
with dichloromethane (3 x 50 ml) and the com- 
bined organic washings were extracted with brine 
until neutral pH. The organic phase was dried on 
anhydrous NasSOa, filtered and stripped to obtain 
a clear oil (4 g) which was crystallized from cold 
hexane to yieid 2.06 g (~~~~ of a white solid, m.p. 
88°C. Characterization by TLC (silica) revealed an 
Rr value of 0.35 (n-~u~H/A~UH~Hz~, 4: 1: I), 
For the final synthesis of compound III, a mixture 
of compound I (780 mg, 0.0039 mol) and com- 
pound II (1.02 g, 0.0054 mol) was dissolved in ab- 
solute ethanol (3 ml). A sequence of freezing, 
evacuating and thawing steps was repeated 3 times. 
The vacuum-sealed mixture was heated at 7O’C for 
3 days. Solvent was removed under reduced 
pressure and the residue obtained was taken up in 
ethyl acetate (30 ml) and extracted with 0.3 N 
KHS04 (2 x 5 ml), followed by brine. The organic 
phase was dried with anhydrous NaBOh, fihered 
and the solvent removed under reduced pressure, 
The final product obtained was a white solid 
(1.35 g, 89Yo) with a melting point of 77°C and an 
& value of 0.47, from TLC (silica) 
ChaClz/MeOH/AcOH (18 : 1: 0.5). 
2.3. Conjugation ofproprunoloi to bovine serum 
albumin 
Deprotection of compound III by removing the 
~-butyloxy~arbo~yl group was performed as 
follows. Compound IfI (100 mg) was taken in a 
CaClz protected flask and treated with thioanisol 
(100 pl), followed by EtOAc (5 ml) saturated with 
HCl gas. After 20 min, the solvent was removed 
under reduced pressure and the residue kept under 
vacuum, over KOH pellets, overnight. Addition of 
dry ether, followed by decantation, gave a residue 
which was used without further manipulation far 
coupling to the bovine serum albumin (BSA), The 
above-mentioned ‘deprotected’ compound III 
(21 mg) was conjugated to BSA by mixing it with 
the coupling reagent dimethyladipimidate (50 mg) 
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in the presence of triethylamine (50 ~1) in methanol mixed well by vortex. After centrifugation at 
(750~1) for 20 min. After removal of the solvent, 3000 rpm for 20 min at 4°C (Sorvall RT6000), the 
the residue was dissolved in methanol (250 ~1) and supernatants were removed by aspiration and the 
the methanolic solution (60~1) was added to a precipitates washed once with 1 ml cold 
solution of 100 mg BSA/ml, 0.1 M pyrophosphate phosphate-buffered saline (PBS). The residue re- 
buffer, pH 8.5. The mixture was stirred at room maining after centrifugation was solubilized in a 
temperature for 2.5 h and the conjugate was total of 300 /cl of 0.1 N NaOH and transferred to 
passed through a Sephadex G-25 column. The final 3 ml Pica-Fluor 30 (Packard) liquid scintillation 
product has a molar ratio of propranolol to BSA cocktail. Radioactivity was measured with a 
of 8. Tricarb liquid scintillation counter. 
2.4. Immunization and cell hybridizations 2.7. Competition between A431 Pz-adrenoceptors 
The propranolol-BSA conjugate was used for 
immunization of BALB/c mice. The procedure for 
immunization and fusion was essentially as 
described [151. The NS-1 myeloma cell line was ob- 
tained from Flow Laboratories. After 14 days in 
the selective medium, cultures secreting mono- 
clonal antibodies to propranolol were isolated, 
cloned and finally propagated in vivo as ascites 
tumor in the peritoneal cavity of BALB/c mice. 
The ascites fluid obtained as well as the culture 
supernatant were used for characterization. 
and McAbs for [3H]propranolol 
2.5. Enzyme-linked immunosorbant assay 
An enzyme-linked immunosorbant assay 
(ELISA) was developed using propranolol-BSA 
conjugate as the antigen for screening purposes. 
The detailed procedures were essentially as de- 
scribed in [la]. The coating buffer used was 
0.05 M NaHCOa, pH 9, and antigen concentration 
used was 1 pg/ml. 
A human epidermoid carcinoma cell line A431 
(kindly provided by Dr Schlessinger of the Weiz- 
mann Institute of Science) enriched with 
&-adrenoceptors (40OOO/cell, Kashles and Levit- 
zki, submitted) was used for binding assays. Con- 
fluent cultures of A431 in 2 cm2 wells were in- 
cubated with 1 pmol [3H]propranolol and dif- 
ferent concentrations of ascites fluid, containing 
either monoclonal anti-propranolol antibodies, or 
a McAb from an irrelevant hybridoma, or unla- 
beled propranolol, in a total volume of 600 pl of 
PBS per reaction well. After an incubation of 1 h 
at 37”C, the reaction mixture was measured, the 
layers of A431 cells washed 4 times with ice-cold 
PBS, dissolved in 0.5 ml of 0.1 N NaOH and 
transferred to 3 ml Pica-Fluor 30 liquid scintilla- 
tion cocktail and radioactivity measured. 
2.0. Fixation of the mAbs to hybridoma ceils 
2.6. Radioimmunoassay for propranolol 
Propranolol as well as other fl-adrenergic 
agonists and antagonists were freshly dissolved 
and diluted in drug-free human plasma converted 
serum. A properly diluted McAb (100 $1) was in- 
cubated with 100 /rl of the propranolol standard or 
cross-reactants of different concentrations, as in- 
dicated in fig.2, at 37°C for 1 h. dl-[4-3H]Pro- 
pranolol hydrochloride (Amersham, spec. act. 
20 Ci/mmol) was added (0.5 pmol/lOOgl per 
reaction mixture, 5 nM) and incubation continued 
for an additional hour at room temperature. The 
following were added in order: 100~1 of 2% nor- 
mal mouse serum; 100 ~1 of 0.1 M NaEDTA, pH 
7.8, and lOO/rl rabbit anti-mouse IgG (1 mg/ml). 
Polyethyleneglycol (MI 6000) was added to a final 
concentration of 10% (w/v). All solutions were 
Hybridoma cells, bearing monoclonal anti- 
propranolol antibodies, were fixed by glutaral- 
dehyde at a final concentration of 2.5%, as de- 
scribed elsewhere (Wang et al., in preparation). A 
total of 2 x 10’ fixed hybridoma cells were in- 
cubated with propranolol or its analogs, as de- 
scribed in the soluble McAb assay. After the ad- 
dition of [3H]propranolol and incubation, the en- 
tire reaction mixture was centrifuged, washed once 
with cold saline and the remaining residue dis- 
solved in 0.5 ml of 0.1 N NaOH. Pica-Fluor 30 
(3 ml) was added and radioactivity measured. 
3. RESULTS AND DISCUSSION 
ELISA was used as the method for screening of 
culture supernatants for anti-propranolol ac- 
tivities. A number of hybridomas were isolated 
175 
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and two clones (P-49 and P-28) were selected for 
characterization. McAb of clone P-49 bound pro- 
pranolol with high affinity - as demonstrated by 
radioimmunoassay (RIA) - possessing a 
preference for the I-stereoisomer of the hapten, as 
opposed to the d form (fig.2). These results are 
reflected in their calculated dissociation constants, 
obtained from Scatchard plots: 1-propranolol, 
3.3 nM, as compared to d-propranolol, 38.6 nM 
(fig.3). It was mono-specific for this antagonist on- 
ly, with minimal cross-reaction to alprenolol (4Oro) 
and with practically no recognition to pindolol, 
practotol or sotalol (fig.4). Moreover, it did not 
react with any of the catecholamines tested such as 
isoprenaline, epinephrine (both l- and d-isomers), 
norepinephrine and phenylephrine (not shown). 
McAb from clone P-28 can also distinguish be- 
tween the stereospecific forms of propranolol 
(table 1). In addition, unlike clone P-49, it 
recognized alprenolol to a large extent (78070) but 
with practically no cross-reaction to other an- 
tagonists or agonists. When the McAb were fixed 
to the hybridoma cells and these cell-bound an- 
tibodies were examined for ligand specificity, it 
was found that the specificity remained almost 
identical to the soluble native antibodies (not 
100 
t 
A I 
+ I \ \ I 
0.01 0.1 1.0 IO 
PROPRANOLOL ADDED (I‘M) 
Fig.2. Reaction of McAb from clone P-49 with the 
isomers of propranolol. (A) I-Propranolol, (0) d- 
propranolol. 
shown). As shown in table 2, both McAbs from 
clone P-28 and P-49 compete with the surface 
,&-adrenoceptors of A431 cells for the binding of 
[3H]propranolol. 
McAb from clone P-49 belongs to mouse IgGl 
subclass and that from clone P-28 to IgGZa, as 
determined by Ouchterlony immunodiffusion. 
BAdrenergic receptors only interact with the l- 
isomer of both agonists and antagonists [lo-131, 
In fact, most, if not all, biological systems 
1 
1 
0 I 2 3 4 
BOUND (ng /ml ) 
Fig.3. Scatchard plot of propranolol binding to McAb 
from clone P-49. (A) l-Propranolol, (0) d-propranolol. 
Fig.4. Specificity of monoclonal anti-propranolol 
antibodies from clone P-49 with some ,&adrenergic 
blockers. R = CH(OH)CHZNHCH(CH&. 
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Table 1 Table 2 
Binding properties of P-28 anti-propranolol antibodies 
&Antagonists or 
agonists 
Antagonists 
dl-Propranolol 
1-Propranolol 
d-Propranolol 
Practolol 
Sotalol 
Pindolol 
McAb P-28 
(070 cross-reaction) 
100 
169 
35 
co.1 
co.1 
co.2 
Competition of monoclonal anti-propranolol antibodies 
with fi-adrenoceptors in the binding of the ligand 
[3H]propranolol 
Competing 
agent 
Monoclonal anti- Irrele- Propra- 
propranolol vant nolo1 
McAb 
P-28 P-49 
(vo of maximum) 
Agonists 
I-Epinephrine co.1 
d-Epinephrine co.1 
Norepinephrine co.1 
Phenylephrine co.1 
Isoprenaline co.1 
RIA were performed as described in the text. The cross- 
reactivity reported here was calculated as the amount of 
dl-propranolol used relative to that needed for each of 
the analogs to cause a 50% inhibition in a standard dose- 
response curve 
associated with recognition of chiral molecules 
show specificity to one isomeric form only. The 
specific ‘arrangement’ of the receptor to ‘accept’ 
only the l-isomer of both the agonists and the an- 
tagonists could possibly be detected im- 
munologically via an anti-idiotype to stereospecific 
anti-antagonist antibodies. Indeed, 1-propranolol 
specific antibodies have been described using the l- 
propranolol-BSA as antigen [17]. In another 
report, a population of l-isomer-specific anti- 
propranolol antibodies was isolated from a pool of 
anti-propranolol antibodies [4]. The same group of 
investigators has recently isolated specific 
monoclonal anti-I-alprenolol antibodies [9]. 
McAb 
@l/reaction) 
0 100 100 100 - 
2 10 25 96 - 
10 3 15 94 - 
Propranolol 
(nM/reaction) 
0 - 100 
1 - - - 80 
10 - - 50 
100 - - 24 
1000 5 
Different concentrations of either McAb to propranolol 
or unlabeled dl-propranolol were added to confluent 
cultures of A431 cells, together with a constant amount 
of (3H]propranolol (5 nM). The radioactivity bound to 
the cells was measured. The data presented here are 
reported as the percent [‘Hlpropranolol bound to the 
cells relative to the control (only [‘Hlpropranolol 
added). 100% is 1500 k 200 cpm/well, where each well 
has 5 x lo5 cells. Non-specific binding was 360 + 
100 cpm/well. Total &adrenoceptor number was 
calculated as 6.1 f 2.1 x IO4 receptors/cell. This value 
is in good agreement with ‘251-cyanopindolol binding 
(Keshles and Levitzki, submitted) 
munogen) equally well, while our McAb from 
clone P-49 cross-reacted with alprenolol only to 
the extent of 4% (fig.4). 
Here we observed a preference of the McAb 
towards the l-isomer, as compared to d- 
propranolol, although the immunogen used was 
the dl-mixture. This type of preferential 
stereospecificity towards the l-isomer has also been 
reported in the case of monoclonal anti-alprenolol 
antibodies [8]. In fact, our results from clone P-49 
were quite similar to that of the McAb from clone 
37A4 [B] and clones 5D9 and 5B7 [9]. However, all 
the three monoclonal antibodies described 
recognized propranolol and alprenolol (the im- 
Using clone P-28, an artificial ‘receptor’ was 
constructed in the form of fixed hybridoma cells 
containing McAb to propranolol. This receptor 
showed similar recognition characteristics towards 
various P-antagonists as the native soluble an- 
tibodies, confirming its being another form of the 
original McAb. It is of interest o note that the af- 
finity of I-propranolol to this artificial receptor 
form of the McAb (& = 4.1 nM) is of the same 
order of magnitude as that of the ‘natural’ ,& 
adrenergic receptor (approximately 1.4 nM) [lo] 
and higher than the affinity of the soluble McAb 
177 
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(20.4 nM). Monoclonal antibodies from both 
clones P-28 and P-49 compete effectively for the 
binding of [3H]propranoloI to A431 ,&-adreno- 
ceptors (table 2), suggesting the ability of these 
McAbs to compete for the drug in vivo. 
in conclusion, our results confirm the notion 
that such monoclonal antibodies, with the same 
stereospecificity as the receptor, could possibly 
serve as the ‘internal image’ of the receptor and be 
used as the first step toward the development of 
anti-idiotype antibodies [ 181, Furthermore, 
monoclonal antibodies with stereospecificity may 
introduce a new concept for the separation of 
racemic mixtures. 
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